MMP13 and Bloom syndrome: Furthermore, the expression level of matrix metallopeptidase 13 (MMP13) which mediates matrix remodeling in vivo, was significantly increased after BLM treatment, and downregulated after OM-MSCs administration (Fig. 2E-F), consistent with data that MMP13 was upregulated in PF patients.